Starting from our powerful AI Platform we managed to develop a powerful diagnosis service.
AI-MCDT (patent pending) is based on advanced Artificial Intelligence (Machine Learning and Deep Learning algorithms) and uses circulating miRNA microarray, NGS or PCR data as input for multi-cancer diagnosis and early detection diagnosis. It is the best non-invasive early-detection test on the market with >99% accuracy for thirteen cancers types, thus increasing treatment efficiency, patient survival rate and lowering costs.
Find out about our multi cancer test (AI-MCDT) and our multiple AI applications.
Patent Pending
Our groundbreaking solution enables early diagnosis and screening for 13 types of cancers, with > 99% accuracy, being the best. The test increases treatment efficiency, patient survival rate, and lowers the costs. It is based on a radically new vision, combining Biomedical Knowledge, Data Science, and advanced AI. It only needs a drop of blood, avoiding the fear, pain, and risks related to the surgical procedures, actually dominating the cancer diagnosis practice.
While our main interest is to validate the cancer tests, we’re also developing a continuously evolving AI platform for omics data analysis. Using various grants, we are planning to add modules for toxicogenomics, microbiomics and pharmacogenomics.
Cluj-Napoca | Str. Alexandru Vlahuta, LAMA C/45 | Romania, CJ 400310
Email: info@aie-op.com